Refractory Plasma Cell Myeloma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Plasmacytoma
  • +2 more
  • Sacramento, California
  • +5 more
2022-04-06
Apr 6, 2022
R
Not yet recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Behavioral Intervention
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-03-28
Mar 28, 2022
A
Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
2022-03-23
Mar 23, 2022
N
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • New Haven, Connecticut
  • +8 more
2022-03-29
Mar 29, 2022
F
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-14
Mar 14, 2022
M
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Scottsdale, Arizona
  • +2 more
2022-03-23
Mar 23, 2022
M
Suspended
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
2022-03-22
Mar 22, 2022
M
Recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Bone Marrow Biopsy
  • +3 more
  • Phoenix, Arizona
  • +2 more
2022-03-22
Mar 22, 2022
C
Active, not recruiting
  • Autologous Hematopoietic Stem Cell Transplant Recipient
  • +4 more
  • Duarte, California
    City of Hope
2022-03-17
Mar 17, 2022
U
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022
U
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022
O
Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-03-11
Mar 11, 2022
E
Active, not recruiting
  • ISS Stage I Plasma Cell Myeloma
  • +4 more
  • Pembrolizumab
  • Radiation Therapy
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
2022-03-02
Mar 2, 2022
F
Not yet recruiting
  • Plasma Cell Myeloma
  • +2 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-01
Mar 1, 2022
N
Completed
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
2022-02-10
Feb 10, 2022
O
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +58 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-02-16
Feb 16, 2022
N
Active, not recruiting
  • DS Stage I Plasma Cell Myeloma
  • +4 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +5 more
  • Scottsdale, Arizona
  • +139 more
2022-02-09
Feb 9, 2022
M
Recruiting
  • Myelodysplastic Syndrome
  • +16 more
  • Computed Tomography
  • +6 more
  • Scottsdale, Arizona
  • +2 more
2022-02-03
Feb 3, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Afatinib Dimaleate
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022